NASDAQ:AVRO

AVROBIO - AVRO Stock Forecast, Price & News

$0.93

-0.01 (-1.06%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.90
▼
$0.96
50-Day Range: $0.69
▼
$0.94
52-Week Range: $0.56
▼
$1.90

Volume: 362,588 shs
Average Volume: 284,247 shs
Market Capitalization: $40.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Institutional Ownership

AVROBIO MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 330.1% Upside
$4.00 Price Target
Short Interest: Healthy
0.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.18) to ($1.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

604th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

95th out of 169 stocks

3.5

Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, AVROBIO has a forecasted upside of 330.1% from its current price of $0.93.
Amount of Analyst Coverage
AVROBIO has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.36% of the float of AVROBIO has been sold short.
Short Interest Ratio / Days to Cover
AVROBIO has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVROBIO has recently increased by 2.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVRO.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for AVRO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
55.74% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to grow in the coming year, from ($2.18) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVROBIO (NASDAQ:AVRO) Stock

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

December 7, 2022 | finance.yahoo.com

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

November 17, 2022 | finance.yahoo.com

AVROBIO to Share Comprehensive Gaucher Disease Program Update

February 4, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

November 8, 2022 | finance.yahoo.com

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022 | finance.yahoo.com

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

October 27, 2022 | finance.yahoo.com

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease

October 25, 2022 | finance.yahoo.com

AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

October 18, 2022 | seekingalpha.com

Avrobio stock rises as gene therapy for Gaucher disease gets ILAP designation in UK - Seeking Alpha

February 4, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

October 18, 2022 | businesswire.com

AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease - Business Wire

October 18, 2022 | finance.yahoo.com

AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease

October 11, 2022 | businesswire.com

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development - Business Wire

October 11, 2022 | finance.yahoo.com

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

October 8, 2022 | businesswire.com

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com

September 27, 2022 | businesswire.com

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress - Business Wire

September 27, 2022 | finance.yahoo.com

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

September 20, 2022 | benzinga.com

AVROBIO Receives Rare Pediatric Disease Designation From FDA For First Gene Therapy In Development For Cy - Benzinga

September 20, 2022 | businesswire.com

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis - Business Wire

September 20, 2022 | finance.yahoo.com

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

September 14, 2022 | businesswire.com

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial - Business Wire

September 14, 2022 | finance.yahoo.com

August 31, 2022 | businesswire.com

AVROBIO to Participate in Four Upcoming Investor Conferences in September - Business Wire

August 31, 2022 | finance.yahoo.com

AVROBIO to Participate in Four Upcoming Investor Conferences in September

August 29, 2022 | reuters.com

AVRO.O - Avrobio Inc | Stock Price & Latest News | Reuters

August 28, 2022 | fool.com

Avrobio, Inc. (NASDAQ: AVRO)

August 17, 2022 | businesswire.com

Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH - Business Wire

August 17, 2022 | finance.yahoo.com

Global Gaucher Disease Treatment Market to Grow at ~5% CAGR during 2022-2031; Market to Expand Owing to Worldwide Prevalence of Gaucher Disease, Rapid R&D Progress, and Government Actions for Therapeutic Advances– Kenneth Research - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Company Calendar

Last Earnings: 11/08/2022
Today: 2/04/2023
Next Earnings (Estimated): 3/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVRO
CUSIP: N/A
CIK: 1681087
Web: www.avrobio.com
Phone: (617) 914-8420
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +330.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -82.47%
Return on Assets: -66.62%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 7.80
Quick Ratio: 7.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.88 per share
Price / Book: 0.24

Miscellaneous

Outstanding Shares: 43,770,000
Free Float: 40,972,000
Market Cap: $40.71 million
Optionable: Not Optionable
Beta: 1.76

Key Executives

Geoff MacKay
President, Chief Executive Officer & Director

Erik John Ostrowski
Chief Financial Officer & Treasurer

Kim Raineri
Chief Manufacturing & Technical Operations Officer

Essra Ridha
Chief Medical Officer

Deanna M. Petersen
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

AVRO Stock - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AVRO shares.
View AVRO analyst ratings or view top-rated stocks.
What is AVROBIO's stock price forecast for 2023?: 1 equities research analysts have issued 1 year target prices for AVROBIO's shares. Their AVRO share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 330.1% from the stock's current price.
View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts.
How have AVRO shares performed in 2023?: AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 30.5% and is now trading at $0.93.
View the best growth stocks for 2023 here.
When is AVROBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVRO earnings forecast.
How were AVROBIO's earnings last quarter?: AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.02.
What other stocks do shareholders of AVROBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?: (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.
What is AVROBIO's stock symbol?: AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."
Who are AVROBIO's major shareholders?: AVROBIO's stock is owned by a number of retail and institutional investors. Top institutional investors include GMT Capital Corp (7.56%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends.
How do I buy shares of AVROBIO?: Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AVROBIO's stock price today?: One share of AVRO stock can currently be purchased for approximately $0.93.
How much money does AVROBIO make?: AVROBIO (NASDAQ:AVRO) has a market capitalization of $40.71 million. The company earns $-119,130,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.
How many employees does AVROBIO have?: The company employs 122 workers across the globe.
How can I contact AVROBIO?: AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for the company is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at ir@ampliphibio.com.

This page (NASDAQ:AVRO) was last updated on 2/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AVROBIO - AVRO Stock Forecast, Price & News

AVROBIO MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AVROBIO (NASDAQ:AVRO) Stock

AVRO Stock News Headlines

AVRO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVRO Stock - Frequently Asked Questions

Overall MarketRank^™